Clinical usefulness of an assay for hepatitis C virus core in the diagnosis of non‐A, non‐B hepatitis and monitoring of the response to interferon therapy
Clinical usefulness of an assay for hepatitis C virus core in the diagnosis of non‐A, non‐B hepatitis and monitoring of the response to interferon therapy
复制标题
丙型肝炎病毒核心检测在诊断非甲型、非乙型肝炎和监测干扰素治疗反应中的临床用途
DOI：
10.1111/j.1440-1746.1994.tb01712.x
复制
发表时间：
1994
影响因子：
4.1
通讯作者：
Tatsuo Sato
中科院分区：
文献类型：
--
作者：
S. Kawano;Motohiko Tanaka;S. Fujiyama;Shinjiro Sato;Y. Taura;M. Goto;H. Chikazawa;Tatsuo Sato
研究了新型JCC-2酶联免疫吸附试剂盒检测和定量抗丙型肝炎病毒(抗-HCV)核心抗体(抗-HCC)的临床应用价值。采集102例各种非甲、非乙型肝病患者的血清标本，其中19例慢性丙型肝炎患者接受干扰素治疗。抗JCC-2抗体检测结果与血清丙型肝炎病毒核糖核酸阳性率显著相关。丙型肝炎病毒核糖核酸阳性患者抗JCC-2抗体阳性率高(急性肝炎72.2%，慢性肝病90%)。慢性肝病不同阶段(CPH、CAH、LC)抗JCC-2滴度几何均值无显著差异。经干扰素治疗后，丙型肝炎病毒RNA转阴者抗JCC-2滴度逐渐下降。如果丙型肝炎病毒RNA阳性复发，抗JCC-2滴度增加，表明连续测定抗JCC-2滴度有助于监测干扰素治疗的抗病毒效果。这些结果表明，用抗JCC-2法定量检测抗肝癌优于半定量检测干扰素治疗所提供的循环丙型肝炎病毒核糖核酸。使用逆转录套式聚合酶链式反应(RT-套式聚合酶链式反应)监测丙型肝炎病毒RNA状态是可能的，但它在技术上要求很高，而且对于常规临床使用来说太昂贵了。
The clinical utility of a new JCC‐2 enzyme‐linked immunosorbent assay kit that detects and quantitates anti‐hepatitis C virus (anti‐HCV) core antibodies (anti‐HCc) was investigated. Serum samples were obtained from 102 patients with various non‐A, non‐B liver diseases, including 19 cases of chronic hepatitis type C who had been treated with interferon (IFN). The results of the anti‐JCC‐2 assay were significantly correlated with serum HCV‐RNA positivity. Patients who were HCV‐RNA positive exhibited a high rate of positivity for anti‐JCC‐2 (72.2% in acute hepatitis, > 90% in chronic liver diseases). The geometric mean of the anti‐JCC‐2 titre was not significantly different among different stages of chronic liver disease (among CPH, CAH and LC). The anti‐JCC‐2 titre decreased gradually in cases that became HCV‐RNA negative after IFN therapy. If HCV‐RNA positivity recurred, the anti‐JCC‐2 titre increased, indicating that serial measurements of the anti‐JCC‐2 titre are useful for monitoring the antiviral effect of IFN treatment. These results suggest that quantification of anti‐HCc by the anti‐JCC‐2 assay is superior to the semi‐quantification of circulating HCV‐RNA provided by monitoring of IFN therapy. Monitoring of HCV‐RNA status using reverse transcription‐nested polymerase chain reaction (RT‐nested PCR) is possible, but it is technically demanding and too expensive for routine clinical use.